Redalpine leads the funding round for the biosensor platform that enables remote and continuous hormone monitoring.
London-based medtech Level Zero Health, which has developed a biosensor platform to allow remote and continuous hormone monitoring, has raised £5.5 million in pre-seed funding. It is the largest amount raised by a European company founded by women.
The round was led by Zurich-headquartered venture capital firm Redalpine along with HAX, part of global venture capital firm SOSV and London-based Entrepreneur First.
Traditional hormone monitoring methods, such as blood tests or at-home urine kits, provide only fragmented snapshots of the biochemical landscape. Urine-based tests capture hormone metabolites with a 12-hour delay, while blood draws are both invasive and impractical for frequent testing. Level Zero Health’s proprietary DNA-based biosensors enable both intermittent and continuous hormone tracking through interstitial fluid – the fluid that surrounds cells and tissues.
The firm was founded in 2023 by ex-Palantir software engineering lead Ula Rustamova and ex-Philips medical device developer Irene Jia.
“Hormones are fundamental to how we live, yet the tools to understand them are decades behind,” said Rustamova. “Our mission is to bridge this gap, empowering individuals and clinicians with real-time insights that have never before been possible.”
Significant potential market
The potential market for Level Zero Health is significant. It is particularly required in the global IVF market which needs blood tests every two to three days per cycle. Testosterone deficiency, which affects 10-40% of men worldwide, also necessitates frequent in-clinic blood testing. The company estimates that the broader continuous biosensing market, including glucose monitoring, is projected to exceed £16 billion globally by 2032.
Level Zero Health says that it has already secured £2.4 million in letters of intent from major IVF clinics, achieved a clinical R&D milestone in hormone detection, developed a working prototype, and filed a broad patent in 2024.
The funding raised will be used to secure approvals for safety, health and environmental protection standards in Europe and the US as a step toward commercialisation. The company is also growing its team and expanding its R&D efforts.
